Fluent, Inc. to Announce 2024 First Quarter Financial Results on May 15, 2024
09 mai 2024 13h19 HE
|
Fluent, Inc.
Fluent, Inc. to Announce 2024 First Quarter Financial Results on May 15, 2024
Inter&Co Inc. Reports Record Profit
09 mai 2024 09h01 HE
|
Inter&Co, Inc
BELO HORIZONTE, Brazil, May 09, 2024 (GLOBE NEWSWIRE) -- Inter&Co Inc. (NASDAQ: INTR | B3: INBR32), the premier financial super app that provides financial and digital commerce services to over...
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
09 mai 2024 08h30 HE
|
Quoin Pharmaceuticals, Inc.
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into...
Acorn’s Q1’24 EPS Improves to $0.03 vs. ($0.03) Loss Per Share on Continued Growth in Remote Monitoring and Control Hardware and Services Revenue
09 mai 2024 07h58 HE
|
Acorn Energy, Inc.
Acorn’s Q1’24 EPS Improves to $0.03 vs. ($0.03) Loss on Continued Growth in Remote Monitoring & Control Hardware & Services Revenue 11am call 844-834-0644
Kelly Reports First-Quarter 2024 Earnings
09 mai 2024 07h30 HE
|
Kelly Services, Inc.
Q1 operating earnings of $26.8 million, or up 34% on an adjusted basis Q1 revenue down following sale of European staffing operations; down 2.6% on an organic basis Q1 adjusted EBITDA margin increased...
Standard Lithium Reports Fiscal Third Quarter 2024 Results, Schedules Investor Update Call
09 mai 2024 07h04 HE
|
Standard Lithium
STRATEGIC EXECUTION SECURES LEADING GLOBAL ENERGY PARTNER, EQUINOR. INJECTS IMMEDIATE LIQUIDITY THROUGH DIRECT INVESTMENTS IN SOUTH WEST ARKANSAS AND EAST TEXAS PROJECTS PARTNERSHIP BRINGS...
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
09 mai 2024 07h01 HE
|
HOOKIPA Pharma Inc.
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and...
LanzaTech Announces First Quarter 2024 Financial Results and Reiterates Full Year 2024 Outlook
09 mai 2024 07h00 HE
|
LanzaTech Inc.
LanzaTech Announces First Quarter 2024 Financial Results and Reiterates Full Year 2024 Outlook
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.
Aveanna Healthcare Holdings Announces First Quarter 2024 Financial Results and Revised 2024 Outlook
09 mai 2024 06h30 HE
|
Aveanna Healthcare Holdings, Inc
First Quarter Revenue was $490.7 million, a 5.2% increase over the prior year Gross margin increased 1.0% to $145.9 million, compared to Q1 2023 First Quarter Net loss was $11.2 million, compared to...